ALPHA(1A)-ADRENOCEPTOR-MEDIATED CONTRACTILE RESPONSES OF THE HUMAN VAS-DEFERENS

被引:44
作者
FURUKAWA, K
ROSARIO, DJ
SMITH, DJ
CHAPPLE, CR
UCHIYAMA, T
CHESSWILLIAMS, R
机构
[1] UNIV SHEFFIELD,DEPT BIOMED SCI,SHEFFIELD S10 2TN,S YORKSHIRE,ENGLAND
[2] ROYAL HALLAMSHIRE HOSP,DEPT UROL,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND
[3] TOHO UNIV,SCH MED,DEPT PHARMACOL,TOKYO,JAPAN
关键词
HUMAN VAS DEFERENS; ALPHA(1)-ADRENOCEPTOR; ALPHA(1)-ADRENOCEPTOR SUBTYPE; WB4101; CHLOROETHYLCLONIDINE; OXYMETAZOLINE; 5-METHYLURAPIDIL;
D O I
10.1111/j.1476-5381.1995.tb16380.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1 The predominant alpha(1)-adrenoceptor mediating contractions of the human vas deferens has been characterised in vitro by use of subtype selective antagonists. 2 Responses of human epididymal vas deferens were obtained to phenylephrine in the presence of amine uptake inhibitors and propranolol. The effects of the alpha(1)-adrenoceptor antagonists, 5-methylurapidil, oxymetazoline, WB4101, prazosin and chloroethylclonidine were examined and also the L-type calcium channel blocker, nifedipine. 3 5-Methylurapidil, WB4101, oxymetazoline and prazosin acted as competitive antagonists of the responses to phenylephrine, yielding pA(2) values of 8.8, 9.2, 7.7 and 8.8 respectively. All four antagonists produced Schild plots with slopes similar to unity and maximum responses to phenylephrine were not altered in the presence of any of the antagonists. 4 Tamsulosin (1 nM) caused rightward shifts of phenylephrine concentration-response curves yielding an apparent pK(B) value of 10.0. However, maximum responses were also reduced by 51% with this concentration of antagonist. 5 Incubation of tissues with chloroethylclonidine (100 mu M for 40 min) failed to alter responses significantly but the presence of nifedipine (1 mu M) reduced maximum responses to phenylephrine by 32%. 6 The high affinity of 5-methylurapidil, oxymetazoline and WB4101, together with the failure of chloroethylclonidine to antagonize responses, indicate that the predominant alpha(1)-adrenoceptor mediating contraction of the human vas deferens has the characteristics previously described for the pharmacologically-defined alpha(1A)-adrenoceptor. The data are also consistent with those described for the cloned alpha(1c)-adrenoceptor subtype thereby supporting the hypothesis that the two receptors are identical. The human vas deferens therefore represents a readily accessible preparation for functional studies of the human alpha(1A)-adrenoceptor.
引用
收藏
页码:1605 / 1610
页数:6
相关论文
共 28 条
[1]   SOME QUANTITATIVE USES OF DRUG ANTAGONISTS [J].
ARUNLAKSHANA, O ;
SCHILD, HO .
BRITISH JOURNAL OF PHARMACOLOGY AND CHEMOTHERAPY, 1959, 14 (01) :48-58
[2]  
BIRMINGHAM AT, 1968, BRIT J PHARMACOL, V34, pP692
[3]   (+)-NIGULDIPINE BINDS WITH VERY HIGH-AFFINITY TO CA-2+ CHANNELS AND TO A SUBTYPE OF ALPHA-1-ADRENOCEPTORS [J].
BOER, R ;
GRASSEGGER, A ;
SCHUDT, C ;
GLOSSMANN, H .
EUROPEAN JOURNAL OF PHARMACOLOGY-MOLECULAR PHARMACOLOGY SECTION, 1989, 172 (02) :131-145
[4]   ALPHA(1)-ADRENOCEPTOR SUBTYPES IN THE HUMAN PROSTATE [J].
CHAPPLE, CR ;
BURT, RP ;
ANDERSSON, PO ;
GREENGRASS, P ;
WYLLIE, M ;
MARSHALL, I .
BRITISH JOURNAL OF UROLOGY, 1994, 74 (05) :585-589
[5]   MOLECULAR-CLONING AND EXPRESSION OF THE CDNA FOR THE HAMSTER ALPHA-1-ADRENERGIC RECEPTOR [J].
COTECCHIA, S ;
SCHWINN, DA ;
RANDALL, RR ;
LEFKOWITZ, RJ ;
CARON, MG ;
KOBILKA, BK .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (19) :7159-7163
[6]   CHARACTERIZATION OF THE ALPHA(1)-ADRENOCEPTORS OF THE RAT PROSTATE-GLAND [J].
COULDWELL, C ;
JACKSON, A ;
OBRIEN, H ;
CHESSWILLIAMS, R .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1993, 45 (10) :922-924
[7]   EXPRESSION OF ALPHA(1)-ADRENOCEPTOR SUBTYPES IN RAT-TISSUES - IMPLICATIONS FOR ALPHA(1)-ADRENOCEPTOR CLASSIFICATION [J].
FAURE, C ;
PIMOULE, C ;
ARBILLA, S ;
LANGER, SZ ;
GRAHAM, D .
EUROPEAN JOURNAL OF PHARMACOLOGY-MOLECULAR PHARMACOLOGY SECTION, 1994, 268 (02) :141-149
[8]   ALPHA-1-ADRENOCEPTOR CLASSIFICATION - SHARPENING OCCAM RAZOR [J].
FORD, APDW ;
WILLIAMS, TJ ;
BLUE, DR ;
CLARKE, DE .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1994, 15 (06) :167-170
[9]  
FORD APDW, 1995, BRIT J PHARMACOL, V114, pP24
[10]  
FURUKAWA K, 1995, BRIT J PHARMACOL, V115, pP128